Your Medicare Plan Might Not Include as Many Freebies Next Year
Insurers are likely to favor margins over growth, meaning benefits such as gym memberships might go.
New York Community Bancorp Went From a Crisis Winner to Banking's Next Worry
The regional lender is seeking funds and considering asset sales after its stock plunged.
New York Community Bancorp Chairman Buys $200,000 in Stock After Tumble
In a filing, the bank said DiNello bought 50,000 shares at a price of about $4.19 a share.
U.S. Bancorp and 15 others fined $81 million for record-keeping failures by SEC
Employees of these companies used "off-channel" communications, like personal text messaging services, to discuss clients and business transactions, rather than official company platforms.
Your Mutual Fund Stinks. Can This Wall Street Invention Change That?
The migration to ETFs has been a nightmare for asset managers, so they're working on a way to entice investors to stick around. It would make good funds better, but it's no salvation for bad ones.
David Solomon Strengthens His Grip on Goldman Sachs
The succession race at the Wall Street firm just got more complicated.
Blue Owl Sees No Threat to Private Credit From Expected Rate Cuts
The firm's private-lending strategy drove double-digit earnings gains throughout last year as investor demand boomed.
ETF Provider Global X Suffers Flurry of Executive Departures
At least six top executives, including investment chief Jon Maier, have left the fund manager since late last year.
Can Dividend Investing Rise From the Dead?
The once-blockbuster strategy of picking big payers has been battered by growth-focused tech titans, but the right approach could bring it back.
Biotech Venture Firm Pitches Startups on Billboards
With startup investment sputtering and many entrepreneurs scrounging for cash, it would seem the last thing a venture-capital firm would need to do is advertise. But that is what biotechnology investor Curie.Bio is doing.
(END) Dow Jones Newswires
02-12-24 0015ET
